908 Devices Receives $2M Order from the Texas Department of Public Safety for Drug Detection and Mitigation

908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces a $2M order from the Texas Department of Public Safety for its MX908 handheld mass spectrometry device. This investment in advanced tools for drug detection builds on an initial order placed last year for several MX908 devices, and is funded through the Community Oriented Policing Services (COPS) grant, a federally funded, state-administered program.

The MX908 provides first responders with fast, actionable information when dealing with unknown threats. It detects and identifies trace amounts of hazardous substances, including synthetic opioids such as fentanyl and nitazenes, counterfeit pills and other illicit drugs in various forms.

"Fentanyl is a national crisis, with fentanyl-related deaths in Texas up 158% from 2020 to 2023,” said Kevin J. Knopp, CEO and Co-Founder, 908 Devices. “We’re proud to support the Texas Department of Public Safety at this critical moment, as communities and all levels of government mobilize to confront the rise of illicit drugs like fentanyl to help save lives.”

This order for multiple MX908 devices shipped in April and these devices will be deployed throughout Texas to critical interdiction locations. Agencies including the Criminal Investigations Division and Narcotics Enforcement will benefit from the technology as they continue to modernize frontline detection capabilities in the face of the opioid crisis.

For more information about 908 Devices and the MX908, visit www.908devices.com.

About 908 Devices

908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in vital health and safety applications, such as the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.

Forward Looking Statements

This press release includes "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under "Risk Factors" and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250422396422/en/